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Abstract 
Cancer is a genetic disease caused by mutations and chromosomal abnormalities which 
contribute to uncontrolled cell growth. In addition, cancer cells can rapidly respond to 
therapies by accumulating novel genetic lesions to gain drug resistance and develop 
relapsing disease. In particular, in chronic lymphocytic leukemia (CLL) diverse chromosomal 
aberrations have been found. Improper repair of DNA double strand breaks (DSBs) is a 
major source for genomic abnormalities.  In this study, we examined the repair of DNA DSBs 
by non-homologous end joining in CLL by performing plasmid based repair assays in primary 
CLL cells and normal B cells as well as TALEN/Cas9 induced chromosomal deletions in the 
CLL cell line Mec1. We show that repair of DNA is aberrant in CLL cells, featuring perturbed 
DNA break structure preference with efficient joining of non-cohesive ends and more 
deletions at repair junctions. In addition, we observed increased microhomology-mediated 
end joining (MMEJ) of DNA substrates in CLL together with increased expression of MMEJ 
specific repair factors. Our results implicate an inherently aberrant DNA DSB repair in the 
acquisition of subclonal genomic structural variations important for clonal evolution and 
treatment resistance in CLL. 
 
Implication 
This study shows that compared to normal B cells, CLL cells have an aberrant DNA ligase 
expression profile, which leads to imprecise and promiscuous DNA end joining likely 
increasing susceptibility for the acquisition of chromosomal aberrations.  
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Introduction 
Whole genome sequencing revealed the presence of numerous clonal and subclonal 
somatic mutations as well as somatic rearrangements in cancer genomes(1-3). Upon cancer 
therapy, subclonal refractory cells harboring acquired novel chromosomal aberrations or 
gene mutations can expand and may thus contribute to therapy resistance and disease 
relapse(4-6). A major source for chromosomal rearrangements are DNA double strand 
breaks (DSBs). DSBs occur constantly during the lifetime of any cell and are normally 
repaired. However, aberrant repair of DSBs can lead to mis-joining of distant DNA ends, 
generating deletions, inversions or complex rearrangements of chromosomes(7;8). DSBs are 
repaired by two major pathways, which are homologous recombination (HR) and non-
homologous end joining (NHEJ). HR utilizes the sister chromatide as template for repairing 
DSBs and is thus primarily confined to S/G2/M phase of the cell cycle, whereas NHEJ simply 
rejoins two DNA ends and, hence, is the main repair pathway for G1 or G0 arrested cells(7). 
For NHEJ, a classical and an alternative pathway are described, termed c-NHEJ and a-NHEJ, 
respectively. While c-NHEJ is dependent on recognition of DNA ends by XRCC5, XRCC6 and 
DNA-PKc and ligation by DNA Ligase 4 (Lig4)/XRCC4, a-NHEJ is carried out independently of 
Lig4 and can probably be executed by a diverse set of factors, including different DNA 
polymerases (δ, θ), DNA nucleases (ERCC1-XPF) and ligases (Lig1, Lig3/XRCC1)(9-11). As a-
NHEJ is frequently associated with short microhomologies (MH) at the site of DNA junctions, 
a-NHEJ is also termed MH mediated end joining (MMEJ). 
Chronic lymphocytic leukemia (CLL) is a B cell malignancy characterized by the progressive 
accumulation of clonal B cells in peripheral blood and lymph nodes. Clinically, the mutation 
status of the B cell receptor divides patients into subgroups with poor (CLL with unmutated 
BCR, CLL-UM) and more favorable prognosis (CLL with mutated BCR, CLL-Mut)(12-14). While 
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many of the hematological malignancies show typical entity-specific chromosomal 
abnormalities(15), there is no specific aberration defining CLL. Instead, in addition to more 
common chromosomal abnormalities like del(17p), del(11q), del(13q) and Tri12, 
conventional cytogenetics as well as novel whole genome sequencing approaches revealed 
a complex set of different chromsomal aberrations in CLL, with CLL-UM samples showing a 
slight increase in the number of aberrations(3;5;6;16-19). 
In this study, we asked whether the frequent occurrence of chromosomal abnormalities is 
associated with an inherently aberrant DNA DSB repair in CLL. To test this, we analysed DNA 
DSB repair in primary CLL cells compared to B cells from healthy controls by assessing in vivo 
repair of artificial DNA substrates carrying diverse DNA break structures using next 
generation sequencing of repair junctions. These results were corroborated by analyzing the 
induction of a large chromosomal deletion using TALEN (Transcription activator-like effector 
nuclease)/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats associated 
protein 9) endonucleases (20). Our data show that DNA end joining is less precise and more 
promiscuous in CLL with a bias towards microhomologies as well as towards joining of 
incompatible DNA ends, likely due to increased expression levels of Lig1 and XRCC1. 
 
Materials and Methods 
Preparation of plasmid repair substrates and transfection of cells. 
Plasmids were generated by cloning synthesized inserts (MWG eurofins) into pAX plasmids 
(sequence shown in supplementary Fig S1). Plasmids were linearized using the respective 
restriction enzymes (Fermentas), gel purified (Qiagen) and transfected into 293 cells 
(genejuice, Novagen) and primary B and CLL cells using nucleofection (Amaxa, Lonza). 72h 
post transfection, cells were harvested and DNA was isolated (Qiagen). Repaired substrates 
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were PCR amplified using high fidelity Phusion polymerase (Biozym) and tagged 3AOX/5AOX 
primers (3AOX 5’-GCA AAT GGC ATT CTG ACA TCC-3’; 5AOX 5’-GAC TGG TTC CAA TTG ACA 
AGC-3’). PCR products were pooled and sequenced on the miseq platform (Illumina). 
pmCherry was generated by cloning the PCR amplified coding region of mCherry (RG1081 
5’-CGCGGGCCCGGGATCGCCACCATGGTGAGCAAGGGCGAGG-3’ and RG1082 5’-
TCTAGAGTCGCGGCC TACTTGTACAGCTCGTCC-3’) into BamHI/NotI digested pEGFP-N1 
(clontech) using In-Fusion HD cloning (Clontech). Plasmids pGFP-1 and pGFP-2 were 
generated by introducing a BsmBI or an EcoRV site at position nt 137 and nt 141 of the GFP 
coding region using PCR-based mutagenesis of the pEGFP-N1 plasmid. Plasmids were 
digested using BsmBI/MfeI (pGFP-1) and EcoRV/PstI (pGFP-2) and gel extracted prior 
transfection together with pmCherry into 293 cells using genejuice transfection reagent or 
nucleofection (Amaxa) as indicated. 6h before transfection, cells were incubated with highly 
specific inhibitors for Lig1/3 (L67), DNA-PKc (NU7441) and PARP (Olaparib, all from 
Selleckchem). After transfection, cells were incubated for further 2 days in presence of 
inhibitors prior analysis for mCherry/GFP expression using flow cytometry (FC500, Beckman 
Coulter). 
 
Gene expression analysis 
RNA was isolated from purified CLL samples and B cells from healthy controls using high 
pure RNA isolation kit including DNase digestion (Roche). The same CLL samples as used for 
plasmid repair assays was used for RNA isolation. First strand cDNA was generated using 
iScript (bio-rad). Gene expression levels in CLL, Mec1 and B cells were determined using 
taqman assays (ThermoFisher) for Lig1 (Hs01553527_m1), XRCC1 (Hs00959834_m1), PARP1 
(Hs00242302_m1) with 18S rRNA as controls (Hs99999901_s1).  
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Nuclease induced chromosomal deletions 
Cas9 constructs specific for chr17 position 41,621,709 (KRT17 locus) were generated by 
cloning annealed oligos (RG1087 5’-ccggGGTGGGTGGTGAGATCAATG-3’ and RG1088 5’-
aaacCATTGATCTCACCACCCACC-3’) into prelinearized pGuide-it-ZsGreen1 Vector (Clontech). 
TALENs specific for chr17 position 40,819,524-40,819,583 (KRT10 locus) were kindly 
provided by Oliver March (Paracelsus Private Medical University Salzburg, Austria). The CLL 
cell line Mec1 (21) was incubated for 6h in RPMI medium supplemented with or without 
30µM Lig1/3 inhibitor L67 followed by Amaxa nucleofection (Lonza) with TALEN/Cas9 
constructs. Cells were kept on RPMI medium supplemented with or without L67 for further 
2 days prior sorting of GFP positive cells on a FACS AriaIII (Beckton Dickinson; purity ≥94.1% 
GFP+) and isolation of DNA (Qiagen). Chromosomal deletions were PCR amplified using 
Phusion polymerase and specific primers (RG1142 5’-TGGCATCTTCTTGGGGTTTA-3’ and 
RG1143 5’-CCACATCCCCTTTTTCCATA-3’). For amplicon sequencing, PCR products from 50ng 
template DNA from two independent experiments were pooled and sent for sequencing on 
the miseq platform (Illumina). For quantification of chromosomal deletions, input DNA from 
cells descending from four independent experiments was titrated from 25ng to 1.56ng and 
subjected to PCR using primers RG1142/RG1143 and HotStar Taq DNA polymerase (Qiagen). 
 
Cells and cell lines 
293 cells, Mec1 cells and primary cells were cultured in RPMI Medium supplemented with 
10% fetal calf serum (Gibco). Mec1 cells were authenticated by DNA fingerprinting and 
cytometrical analysis of surface markers (DSMZ). After purchase, stocks of Mec1 cells were 
frozen and passaged less than 6 months. 293 cells were provided by Stefan Hainzl (EB House 
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Austria, Salzburg) and periodically authenticated by morphologic inspection. Mec1 and 293 
cells were confirmed by fingerprinting at the DMSZ (Braunschweig, Germany) on October 9th 
2017. Mec1 and 293 cells were tested negative for mycoplasma in September 2017 using 
PCR based mycoplasma detection from cell culture supernatants (PanReac AppliChem). 
Primary cells were isolated from peripheral blood of CLL patients upon informed consent 
according to the national guidelines and of the ethics committee and according to the 
declaration of Helsinki (Ethics committee approval Salzburg: 415-E/1287/4–2011, 415-
E/1287/8–2011). CLL cells and B cells were purified untouched using EasySep system 
(StemCell Technologies) or MACS (Miltenyi Biotec). Patient characteristics are summarized 
in supplementary table S1. The determination of prognostic markers and FISH analysis for 
trisomy 12, del11q, del13q, del17p was performed routinely at our department as 
previously described(22). In addition, FISH and karyogram analysis of sample 9956 (patient 
ID660) was performed at the laboratory for molecular biology and tumor cytogenetics at the 
Ordensklinikum Linz, Seilerstätte 4, 4010 Linz, Austria. 
For cell cycle analysis, purified B and CLL cells were stained using CD5-FITC (clone: UCHT2; 
eBioscience) and CD19-PE/Cy7 (clone: SJ25C1; eBioscience)  antibodies in PBS at room 
temperature. Cells were resuspended in prewarmed RPMI without Phenol-Red and stained 
with vybrant cell cycle dye (Vybrant® DyeCycle™ Violet Stain, V35003; ThermoFisher) for 1h 
at 37°C followed by immediate analysis by flow cytometry (Gallios, Beckman Coulter) 
 
Sequence analysis and Bioinformatics. 
Paired end fastq files were acquired by eurofins genomics and GATC-Biotech (Germany). 
Raw reads were trimmed and selected for paired reads using Trimmomatic v0.33(23)(PE 
mode, -phred 33,TRAILING:4), resulting in 8,378,777 paired reads surviving (95.56 % of input 
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reads). Forward and reverse reads were merged using FLASh v1.2.11(24) (-r 300 –f 350 –s 
35) and 6,932,326 stiched sequences remained for further analysis. Only merged reads 
flanked by forward and reverse primers were regarded for further data analyses (only 
<0.001% of the resulting sequences were forward-forward or reverse-reverse primed; 
supplementary table S5). To avoid missing imprecise repair junctions of resected substrates, 
we decided to use the unique 6 bp stretch 3’ of the conserved primer binding sites for 
mapping. Analyses of read length, frequency and sequence were performed using custom 
BASH and PERL scripts, which can be provided upon request. Sequence alignment for 
detection of deletions was perfomed using MAFFT alignment program(25). Circos plots were 
created in R using the circlize package (v0.3.8). All other graphs were created in Graph Pad 
Prism 5 and Inkscape v0.91. 
 
Results  
Next generation sequencing-assay for detecting repair of different DNA end structures 
To test the efficiency of DSB repair, we set up a plasmid based repair assay, consisting of a 
pool of nine plasmids which harbor individual 350bp inserts flanked by conserved primer 
binding sites (Fig 1A, supplementary Fig S1). Upon digestion with respective restriction 
enzymes, the individual plasmids yield defined DNA break structures ranging from blunt 
ends with and without a 6bp microhomology to cohesive and non-cohesive 3’ and 5’ 
protruding ends with 4 nt overhangs (Fig 1B). Upon transfection into primary cells, the linear 
DNA substrates are recognized by the DNA DSB repair machinery and rejoined. The resulting 
repair junctions can subsequently be PCR-amplified using the conserved primer binding sites 
and analysed by next generation sequencing (NGS). As each of the nine plasmids harbors a 
unique DNA sequence between the conserved primer binding sites, all reads obtained by 
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NGS can be exactly mapped to the respective plasmids, allowing examination of efficiency 
and accuracy of DNA repair in context of DNA end structures and microhomologies. 
 
DSB repair favors incompatible DNA ends in CLL cells 
To detect aberrant DSB repair in CLL cells, we used our pool of linearized plasmid substrates 
to nucleofect primary CLL cells (CLL-Mut n=4, CLL-UM n=3;  patient details shown in 
supplementary table S1) and B cells from healthy controls (n=3). Three days after 
nucleofection, we isolated DNA and PCR amplified repair junctions from each sample. 
Notably, we observed repaired substrates immediately after nucleofection in some CLL 
samples, which is in line with published data on rapid end joining of DNA ends (Fig 1C)(26). 
Upon NGS of pooled amplicons, we obtained a total of 2.676,354 reads, ranging from 
96,000 to 587,418 reads for all samples (Fig 1D). 
By calculating the ratio of inter- to intramolecular repair events, we surprisingly obtained a 
robust bias towards intermolecular repair junctions in CLL samples, irrespective of the BCR 
mutation status (CLL-Mut and CLL-UM), whereas normal B cells preferred an intramolecular 
repair (ratio inter/intramolecular repair CLL mean 1.88±0.71 STD; B cells 0.79±0.22, p=0.017 
Mann Whitney test; Fig 2A). In particular, we observed significantly increased 
intermolecular repair of incompatible DNA ends in CLL cells compared to B cells (eg joining 
of plasmid #6 with plasmid #2 or plasmid #8 with plasmid #5) whereas compatible 3’ and 5’ 
overhangs or blunt ends were repaired at comparable efficiency (Fig 2B; supplementary 
table S2). None of the repair junctions were significantly overrepresented in B cells 
compared to CLL cells (Fig 2B; supplementary table S2). Also by analyzing only 
intramolecular repair frequencies of the nine different DNA break structures, we observed 
that non-cohesive 5’ ends (substrate #5) as well as incompatible 3’-5’ overhangs (substrate 
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#7) were repaired with significantly higher efficiency in CLL cells compared to B cells 
(substrate #5: CLL mean percentage of reads 4.8±2.4 STD, B cells 0.7±0.5; p=0.004; substrate 
#7: CLL mean 12.4±5.6 STD, B cells 2.5±2.4; p=0.005 two-tailed t-test assuming unequal 
variances; Fig 2C and supplementary table S3). 
 
More end resection occurs during DSB repair in CLL cells 
We next aimed at determining differences in the occurrence of deletions at repair junctions 
between CLL and B cells, resulting from joining of end resected DNA ends. Therefore, we 
first identified the most frequent repair junction for CLL-Mut, CLL-UM, and B cells for all 
individual intramolecular repair events and mapped all shorter sequences to the most 
frequent consensus. We thereby found that the most frequent repair junctions of the nine 
DNA substrates were the same within each sample group (CLL-Mut, CLL-UM, B cells; Fig 3A): 
blunt ends - irrespective of a 6bp microhomology – and cohesive 3’ and 5’ ends were 
preferably simply rejoined, whereas 1bp microhomologies were preferentially used when 
repairing non-cohesive 3’ (substrate #3, Fig 3A) and 5’ overhangs (substrate #5, Fig 3A).  
Incompatible 3’-5’ overhangs (substrate #7), 3’ overhang/blunt and 5’ overhang/blunt ends 
(substrate #8 and #9) were preferentially joined and the ssDNA gaps filled up (Fig 3A). 
We next graphically illustrated the occurrence of deletions at repair joints which we 
discerned by NGS. In all cases, deletions clustered around the repair junction of the most 
frequent consensus sequences (Fig 3B). By comparing the median numbers of resected 
bases (deletions) at repair junctions, we found that deletions were significantly more 
frequent in CLL cells compared to B cells (differences in the median number of deleted 
bases per sequence were significant with p<0.0001 between CLL-Mut and B cells and CLL-
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UM and B cells for each substrate; except substrate #4 CLL-UM versus B cells: p=0.13; 
Wilcoxon rank sum test with continuity correction; Fig 3C).  
 
DNA DSB repair is skewed towards MMEJ in CLL 
Upon analyzing the sequences harboring deletions at the repair junction, we observed a 
high incidence of 1-9bp microhomologies flanking the deleted region irrespective of the 
sample group (CLL and B cells; supplementary Fig S2). As these microhomologies could at 
least in part derive from repair by MMEJ and as deletions were occurring at higher incidence 
in CLL (Fig 3), this prompted us to test whether the MMEJ pathway is generally more active 
in CLL compared to B cells. To this end, we more thoroughly analysed repair junctions of 
substrate #2, featuring a 6bp microhomology at both DNA ends. As already shown by 
Verkaik and coworkers using a similar approach, repair by the MMEJ pathway leads to 
deletion of one of the two 6bp microhomologies, whereas repair by c-NHEJ results in direct 
joining of the DNA ends, yielding a direct repeat of 6bp within the repair junction(27). 
Hence, calculating the ratio of the number of junctions deriving from 6bp microhomology 
mediated versus direct joining of substrate #2 reflects MMEJ versus c-NHEJ activity. As 
shown in Fig 4A, we found that direct joining of substrate #2 was the preferred repair 
mechanism in CLL as well as in B cells, however, repair by MMEJ was significantly increased 
relative to c-NHEJ in CLL cells, irrespective of BCR mutation status (ratio microhomology-
mediated/direct joining of substrate #2 for CLL: mean 0.067±0.023 STD, B cells 0.024±0.005 
STD; p=0.017 Mann Whitney test; Fig 4A). 
 
Efficient joining of incompatible DNA ends in CLL is not exclusively dependent on 
microhomologies 
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Next, we tested whether CLL-specific efficient joining of incompatible DNA ends was solely 
dependent on MH-based repair of end-resected substrates. To test this, we only considered 
repair junctions mapping to the most frequently occurring sequence of a particular repaired 
substrate and calculated their relative frequencies, without considering repair of resected 
substrates. Thereby we found that again various incompatible DNA ends were more 
efficiently repaired in CLL cells compared to B cells, leading to a total of 12 junctions which 
were significantly overrepresented in CLL samples (Fig 4B and supplementary table S4). 
Again, none of the repair events were significantly overrepresented in B cells compared to 
CLL cells (Fig 4B and supplementary table S4). Though 7 out of these 12 junctions revealed 
short microhomologies (1 to 5 nt, supplementary table S4), 5 of these junctions were 
generated by direct intermolecular joining of 3’-5’ overhangs or 5’ overhang-blunt ends, 
implying that incompatible DNA ends were more efficiently joined in CLL cells also 
independent from terminal microhomologies (Fig 4C, supplementary table S4). 
To elucidate the underlying mechanism for biased DSB DNA repair in CLL cells, we first 
analysed cell cycle stages in CLL and B cells (supplementary Fig S3). However, both CLL 
samples as well as B cells were mostly in G1 phase (range 90.2-95.2% for CLL; 87.5-97.5% for 
B cells) with no apparent cell cycle differences (supplementary Fig S3). We next examined 
expression levels of key factors involved in MMEJ and c-NHEJ in CLL and B cells (9). By 
extracting data from Haslinger and coworkers(28) using the oncomine database(29)  
(www.oncomine.org), we found that several genes, including PARP1, XRCC1 (forming a 
complex with Lig3) and Lig1, which all are involved in MMEJ were significantly upregulated 
in CLL compared to normal B cells (Fig 5A). In contrast, within the set of factors involved in 
c-NHEJ, only DNA-PKcs (PRKDC) and PARP3 showed a slight but significant overexpression in 
CLL and none of the factors examined showed downregulation in CLL (Fig 5A). To validate 
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expression of MMEJ factors in our CLL samples, we performed realtime RT-PCRs. 
Consistently, Lig1, XRCC1 and PARP1 were all higher expressed in CLL samples compared to 
B cells from healthy donors (supplementary Fig S4). As increased expression levels of MMEJ-
specific factors could likely be causative for our observed bias towards MMEJ in CLL cells, we 
finally wanted to test whether PARP1, Lig1 or Lig3/XRCC1 could also contribute to MH-
independent joining of incompatible ends, in particular intermolecular joining of 5’ 
overhangs with blunt ends which we particularily observed to be increased in CLL samples 
(Fig 4B, C). Therefore, we performed a 293 based assay for direct joining of two GFP-based 
reporter constructs (pGFP-1 and pGFP-2) which encode a functional GFP protein only upon 
intermolecular direct joining of pGFP-1 (encoding the N-terminal portion of GFP with a 4 nt 
5’ overhang) and pGFP-2 (encoding the C-terminal portion of GFP starting with a blunt end) 
(Fig 5B). GFP expression based on direct joining of pGFP-1/pGFP-2 was analysed in presence 
of specific inhibitors targeting PARP (Olaparib), Lig1/3 (L67), and DNA-PKc (NU7441) as 
control. To normalize for transfection efficiencies, we cotransfected a plasmid encoding 
mCherry (pmCherry). As expected, direct repair of the GFP plasmids was strongly impeded 
by inhibition of DNA-PKcs, which are central to c-NHEJ. To a lesser extent also inhibition of 
Lig1/3 showed an effect on direct pGFP-1/pGFP-2 joining, while inhibition of PARP family 
proteins by Olaparib had no effect on DNA repair in this assay (Fig 5C). 
 
Induction of chromosomal deletions in the CLL cell line Mec1 is impaired upon inhibition 
of Lig1/3 
Finally, we tested whether Lig1 or XRCC1/Lig3 is involved in the generation of chromosomal 
deletions between a 5’overhang DNA DSB and a blunt end DNA DSB in CLL. Therefore, we 
transiently transfected the CLL cell line Mec1 with constructs expressing TALENs (generating 
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a 5’overhang) and Cas9 (generating blunt end DSBs), which both cleave at chromosome 17, 
with or without treatment with 30µM Lig1/3 inhibitor L67 (Fig 6A). Of note, realtime RT-PCR 
revealed that in Mec1 cells, MMEJ specific factors Lig1, XRCC1 and PARP1 were also more 
abundantly expressed than in normal B cells (supplementary Fig S4). We positively sorted 
transfected cells based on GFP expression from the Cas9 construct and estimated 
chromosomal deletion frequencies of a large 0.8Mb fragment by PCR on serially diluted 
input DNA isolated from sorted cells  (Fig 6A, B). As estimated from four independent 
experiments, the chromosomal deletion frequency of L67 treated cells was  lower compared 
to untreated cells, as amplification of breakpoint junctions failed from 1.56ng input DNA of 
L67 treated cells in all experiments, whereas in two of four experiments, PCR amplified 
breakpoint junctions were detectable in untreated cells at that DNA concentration (Fig 6B). 
Amplicon sequencing of the PCR products from two experiments revealed that L67 treated 
Mec1 cells had an increased frequency of short (5-49bp) deletions at the breakpoint 
junction, whereas large (≥50bp) deletions were reduced (Fig 6C), again pointing to 
involvement of Lig1/3 in the occurrence of large deletions at repair joints. Small (0-4bp) 
deletions, likely resulting from direct joining or deletions within the 5’ overhang were also 
reduced in L67 treated cells (Fig 6C). 
Thus, we infer that the described overexpression of Lig1 or XRCC1 in CLL could explain the 
observed bias towards both, MMEJ as well as increased repair of incompatible DNA ends 
with increased deletions at repair junctions. 
 
Discussion 
Aberrant repair of DSB can lead to genetic changes, driving carcinogenesis and clonal 
evolution of cancer. Here we describe several differences of DSB repair in B cells versus CLL 
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cells by applying a plasmid based repair assay analyzed by NGS as well as by assessing repair 
of TALEN/Cas9 induced chromosomal deletions in the Mec1 cell line. While plasmid based 
assays have been used in the past to investigate DSB repair in cell lines and cancer 
cells(27;30;31), our NGS based approach allowed simultaneous analysis of efficiency and 
accuracy of DSB repair in regard to diverse DNA break structures and the cellular context at 
single nucleotide level. In general, our assay revealed that complementary 5’ protruding 
ends as well as blunt ends exhibited highest repair efficiency and 3’ cohesive and 3’ non-
cohesive staggered ends showing weakest joining efficiency. Weak repair of 3’ overhangs 
was noted in earlier studies(31), probably because 3’ overhangs rather promote 
homologous recombination (HR) as they are required for strand exchange reaction in 
HR(32;33). However, our repair assay revealed a complex set of substantial differences in 
efficiency as well as precision of DNA repair in CLL vs B cells. In addition to the frequent 
occurrence of deletions at the repair junction, which was already described for leukemic 
cells(30), our assay revealed that non-cohesive protruding ends were joined significantly 
more efficiently in CLL cells compared to B cells. 
In our study, efficient joining of incompatible ends was attributed to increased MMEJ 
activity, reflected by the presence of short microhomologies within repair junctions of end 
resected incompatible DNA substrates. Concurrently, a 6bp microhomology was 
preferentially used in CLL cells for repair of DNA substrates. These results indicate that DNA 
DSB repair is skewed towards MMEJ in CLL, which is corroborated by overexpression of 
MMEJ specific factors in CLL. Notably, this skewing towards MMEJ does not result from cell 
cycle differences, as nucleofected CLL cells in our analysis were also G1 arrested. We further 
observed CLL-specific increased joining of incompatible DNA ends independent from end 
resection and usage of microhomologies. Strikingly, this increased joining efficiency was 
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especially pronounced in intermolecular repair events, indicating a somehow increased 
promiscuity in DNA end joining. While MMEJ classically involves end resection of DNA 
overhangs after stabilization of the paired homologous region by several nucleases(34;35), 
direct joining of incompatible protruding ends can be mediated by two possibilities: either 
DNA ends are blunted prior to DNA joining (refilled or resected) or otherwise DNA is re-
synthesised across a stabilized DNA junction of two staggered DNA ends by polymerase µ or 
λ, followed by ligation of DNA nicks(36-38). While ligation of blunted dsDNA ends is 
normally mediated by Lig4/XRCC4, nick sealing is efficiently performed by Lig1 and 
Lig3/XRCC1 complexes (39;40). Our pGFP-1/pGFP-2 repair assay revealed that while most 
repair events are catalyzed by c-NHEJ involving DNA-PKcs, repair could partly be mediated 
by polymerase-dependent DNA synthesis across direct pGFP-1/pGFP-2 junctions followed by 
nick-sealing by Lig1/3. In that way, overexpression of Lig1/3 could not only contribute to 
increased MMEJ but also to direct joining of incompatible DNA ends. Lig4 deficient cell lines 
are still able to repair DNA DSBs, albeit the number of direct joints are decreased and MH 
usage is increased due to activity of Lig1/3 (41;42). While sole activity of Lig1/3 in Lig4 
deficient cells led to a higher frequency of endonuclease induced translocations in rodent 
cell lines, the frequency in human cell lines was decreased, showing that efficiency and 
kinetics of DNA DSB repair is likely depending on cell type and species specific expression 
levels of repair factors (41;43). Our own data suggest that Lig1/3 may significantly 
contribute to the formation of TALEN/Cas9 induced large chromosomal deletions in the CLL 
cell line Mec1 as we observed a reduction in their occurrence upon Lig1/3 inhibition, 
together with a reduction in large deletions at repair joints. Hence, our results would 
propose that CLL specific increased expression levels of the MMEJ factors Lig1 and XRCC1 
could contribute to increased propensity to acquire chromosomal aberrations during DNA 
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DSB repair. This fits with the observation that chromosomal aberrations are frequently 
found to be subclonal in CLL, pointing to their successive generation during disease 
progression (6). In addition, an increased MMEJ activity could also explain the formation of 
small deletions and microdeletions frequently observed in CLL(44) and also in other cancer 
entities (45). These deletions often exhibit sequence homologies at breakpoint junctions, 
suggesting that they likely arise due to MMEJ of DNA DSBs. Alternatively, they could occur 
by polymerase slippage during replication (46;47). As we observed several differences in 
end joining between CLL and B cells, it would be certainly interesting to screen DNA repair 
quality/quantity in therapy sensitive versus refractory samples as well as in other clinically 
relevant CLL subsets (such as samples with complex karyotype). Deriano and coworkers 
already reported increased error-prone end joining of DNA ends in CLL cells obtained from a 
therapy resistant patient (48). Hence, it is conceivable that CLL subset or risk group specific 
differences in DNA DSB repair could contribute to diverse clinical outcomes.  
Although a portion of CLL patients exhibits mutations at DNA repair genes (6), our data 
rather suggest an inherently aberrant DNA DSB repair activity in CLL due to different 
expression levels of key factors for MMEJ, in particular as we excluded del(11q) and del(17p) 
patients (harboring deleted ATM and p53 genes) and as all samples included in our analyses 
showed a very uniform pattern of repair junction formation, irrespective of the BCR 
mutation status. 
Summarizing, we could identify profound differences in efficiency and precision of DSB 
repair between CLL cells and normal B cells. Considering a reported increased formation of 
DNA DSBs in precancerous lesions and cancers(49), their imprecise repair due to increased 
Lig1 and XRCC1 levels could thus continuously enhance the formation of genomic 
aberrations, contributing to clonal evolution and chemoresistance. Hence, concomitant 
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usage of Lig1/3 inhibitors during CLL treatment would not only potentiate cytotoxicity of 
DNA damaging agents (50) but might also impede clonal evolution by acquisition of novel 
genomic rearrangements. 
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Figure legends 
Figure 1. Plasmid based DSB repair assay. (A) Schematic representation of plasmid based 
DSB repair. Circular plasmids are linearized upon digestion with restriction enzymes 
followed by transfection of cells where substrates are rejoined. Repair junctions are 
detected by PCR using conserved forward (fwd) and reverse (rev) primer binding sites on 
the plasmids. (B) DNA end structures of substrates used in our DSB repair assay (MH: 
microhomology of 6bp). (C) B cells and CLL cells were transfected with our pooled repair 
substrates #1-#9. DNA was isolated 72h (left panel) or 0h and 72h (right panel) post 
transfection and repair junctions were PCR amplified and run on an agarose gel. Amplicons 
corresponding to a 300bp band were gel excised and analysed by NGS. Asterisks refer to 
bands corresponding to amplified undigested plasmids. Amplicons from a control PCR on 
TP53 are loaded to show integrity of isolated DNA. (D) Number of reads obtained by NGS of 
the respective amplicons is shown.  
 
Figure 2. DNA DSB repair in B cells and CLL cells. (A) Graph shows the ratio of inter- to 
intramolecular repair junctions. (B) Inter- and intramolecular repair events are depicted as 
circos plots for CLL cells and for normal B cells. The nine segments represent the nine 
different plasmids used in our repair assay. The size of the segments reflects their relative 
occurrence from NGS analysed repair junctions. Repair frequencies are indicated by size of 
ribbons, where orientation of repair of the respective substrates is given by arrowheads at 
the end of ribbons (mean values for CLL and B cells as shown in supplementary table S2 
were used for generating plots; start of ribbon denotes forward primed arms; arrowhead of 
ribbon denotes reverse primed arm of substrates shown in supplementary Fig 1). Repair 
junctions significantly overrepresented in CLL cells compared to B cells (and vice versa) are 
colored red (p<0.05; two-tailed t-test with unequal variances) and light red (0.05≤p<0.1), 
and the correspondingly underrepresented repair junctions are colored blue (p<0.05; two-
tailed t-test with unequal variances)  and light blue (0.05≤p<0.1), respectively. (C) The 
frequency of intramolecular repair junctions for individual substrates is shown. Asterisks 
indicate significant differences between CLL and B cells (substrate #5: p=0.004; substrate #7: 
p=0.005 two-tailed t-test with unequal variances). 
 
Figure 3. Deletions at repair junctions. (A) The most frequent repair junction for individual 
substrates is indicated. 1bp microhomologies used for repair are indicated in red. (B) Graphs 
show the occurrence of deletions at repaired substrates as horizontal lines. Y-axis gives the 
frequency of deletions and x-axis indicates the position of the deletion within the amplicon. 
(C) All sequences obtained for the respective sample cohort were analyzed based on 
deleted sequence lengths. Box plots show the median length of deletions within the 25th 
and 75th percentile (box) and data within a 1.5 times interquartile distance from the median 
as whiskers. Outliers (all other data points) are indicated as circles. 
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Figure 4. Microhomologies at repair junctions. (A) Ratio of repair junctions deriving from 
microhomology mediated joining (6bp microhomology, MH) versus direct joining of 
substrate #2 from transfected CLL and B cell samples. Asterisks indicates significant 
difference between CLL and B cells (p=0.017 Mann-Whitney test). (B) The most frequently 
used sequence for each of all individual inter- and intramolecular repair events are depicted 
as circos plots for CLL cells and for normal B cells. Circos plots were generated as indicated 
for Fig 2 (sequences shown in supplementary table S4). (C) Repair junctions which were 
significantly overrepresented in CLL (p<0.05 from B) are schematically depicted. The hash 
mark specifies the respective forward-primed (red) and reverse-primed (yellow) DNA 
substrate. Arrows indicate gap filling by DNA polymerases. 
 
Figure 5. DNA DSB repair of non-resected DNA substrates. (A) Expression values for factors 
involved in MMEJ (left panel) and c-NHEJ (right panel) are shown as fold change between 
CLL and B lymphocytes. >2-fold differences are shaded grey. Significances are indicated 
above each bar. (CLL n=100; B cells n=11). (B) schematic representation of plasmids (GFP-1 
and GFP-2) used to detect intermolecular repair of blunt/5’overhang junctions. Direct 
intermolecular repair of non-resected plasmids leads to GFP expression. (C) 293 cells were 
transfected using plasmids GFP-1 and GFP-2 shown in (B) together with a plasmid expressing 
mCherry. Representative FACS plots show GFP/mCherry expression in presence of 
inhibitors. Data within plots gives percentage of GFP+-cells within all mCherry+-cells. Graph 
shows the results from three independent FACS experiments. UTR1: untreated cells 
transfected using GeneJuice (controls for NU7441, Olaparib treated cells). UTR2: untreated 
cells transfected using nucleofection (controls for L67 treated cells). neg: cells transfected 
with mCherry plasmids only. Significant differences in comparison to untreated controls is 
indicated above the respective dataset (two-tailed t-test with unequal variances).  
 
Figure 6. Induction of chromosomal deletions by TALEN/Cas9 generated DNA DSBs are 
dependent on Lig1/3. (A) Schematic representation of chromosomal deletions induced by 
TALENs/Cas9 constructs. Binding sites of TALENs and Cas9 constructs are shaded red and 
green, respectively. Genomic position and sequence of binding sites are shown in 5’-3’ 
orientation. The protospacer adjacent motif is colored blue. Specific primers for 
amplification of breakpoint junctions are given as black arrows on chromosome 17, yielding 
an approximate 180bp PCR product in case a 0.8Mb fragment of chr17 is deleted. (B) 
Limiting dilution of genomic DNA to estimate the frequency of chromosomal deletions after 
expression of TALEN/Cas9 constructs in Mec1 cells treated with 30µM Lig1/3 inhibior L67 or 
untreated controls. PCR amplification was performed with serial dilutions of genomic DNA 
from four independent experiments as template (25, 12.5, 6.25, 3.125, and 1.56ng). A 
agarose gel from one experiment is shown. The number of times a PCR fragment was 
detected from four independent experiments is indicated below the gel. n.t.=Mec1 cells not 
transfected with TALEN/Cas9 constructs. (C) PCR products from two experiments were 
amplicon sequenced and fragment lengths were analysed (Mec1: 1,191,602 reads; Mec1 
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L67 treated: 177,319 reads). The percentage of reads with the respective amount of end 
resection are depicted in separate graphs, demonstrating the occurrence of about 8 times 
more fragments with large deletions (≥50bp) at breakpoint junctions. Percentages are 
indicated above the bars. (Reads with insertions at breakpoints are not depicted). 
 






